A股異動丨廣信材料(300537.SZ)跌4.31% 提示風險稱光刻膠項目尚在研發階段
格隆匯10月13日丨廣信材料(300537.SZ)跌4.31%,報28.18元,總市值54.4億元。廣信材料昨日發佈公告提示風險稱,公司光刻膠項目尚在研發階段,全面實現在中國大陸地區直接生產銷售尚需時日,預計不會對公司2020年營業收入和經營業績造成重大影響。項目從技術開發到生產銷售仍需要生產建設、資金籌劃、市場開拓等前期準備工作,後續還需要經過試產、小批量生產、量產的過程,需要較長時間且相關手續繁雜,存在不確定性;公司研發的光刻膠產品最終是否能被客户廣泛認可並最終進入其採購體系尚需要公司技術、市場部門在較長的時間裏進行技術攻關和市場開拓,能否大規模進入市場尚存不確定性。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.